Yangxue Qingnao pill

PreclinicalSmall molecule

Yangxue Qingnao pill is one of 76 small molecule programs targeting Cognitive impairment. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cognitive ImpairmentActive, not recruiting

Headache DisorderActive, not recruiting

Cerebral InfarctionActive, not recruiting

Cognitive ImpairmentPreclinical

Active, not recruiting

Headache DisorderPreclinical

Active, not recruiting

Cerebral InfarctionPreclinical

Active, not recruiting

Competition

Competitive Landscape

279 competitors in Cognitive Impairment

#DrugCompanyPhaseTrials

Actos

Takeda

Phase 3

3 2

Farxiga

AstraZeneca

Phase 3

1 3

Provigil

NNuvo Research GmbH

Phase 3

1 4

Xarelto

WWim Janssens

Phase 3

1 5

Aquasol E

NNational Eye Institute (NEI)

Phase 3

1 6

Viagra

VViatris Specialty LLC

Phase 3

1 7

Donepezil Hydrochloride

Eisai

Phase 3

3 8

Statins

Sanofi

Phase 3

1 9

Galantamine Hydrobromide

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

4 10

Karxt

Bristol-Myers Squibb

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2032

Recruiting

Headache

NCT05334927

Clinical

Trials by Indication[1]

Cognitive impairment1 trial

Treatment of Mild Vascular Cognitive Impairment With Yangxue Qingnao Pill

Completed·PPeking University Third Hospital·N/A·NCT04958512·60 enrolled

Cerebral Infarction1 trial

Effectiveness of Yangxue Qingnao Granules in Preventing Post Thrombolytic Hemorrhage Transformation in Patients With Acute Cerebral Infarction

Unknown status·PPeking University Third Hospital·N/A·NCT06344312·60 enrolled

Headache1 trial

China HeadAche DIsorders RegiStry

Recruiting·BBeijing Tiantan Hospital··NCT05334927·10,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Yangxue Qingnao pill. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Yangxue Qingnao pill compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Yangxue Qingnao pill. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking University Third Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: PPeking University Third Hospital

Yangxue Qingnao pill

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2032

Trials by Indication[1]

Cognitive impairment1 trial

Cerebral Infarction1 trial

Headache1 trial

References

Drug Info

Quick Facts

Related News